IRIS
CHIMENTI, MARIA SOLE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 35.587
EU - Europa 2.675
AS - Asia 840
OC - Oceania 15
SA - Sud America 13
AF - Africa 4
Continente sconosciuto - Info sul continente non disponibili 4
Totale 39.138
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 35.555
CN - Cina 586
IE - Irlanda 475
IT - Italia 437
UA - Ucraina 404
DE - Germania 385
FR - Francia 335
GB - Regno Unito 176
SE - Svezia 124
KR - Corea 109
PL - Polonia 98
FI - Finlandia 89
RU - Federazione Russa 50
BE - Belgio 47
IN - India 24
UZ - Uzbekistan 24
CA - Canada 22
IR - Iran 16
AU - Australia 14
JP - Giappone 14
ES - Italia 12
HK - Hong Kong 11
MX - Messico 10
SG - Singapore 10
VN - Vietnam 9
BR - Brasile 8
PK - Pakistan 7
RO - Romania 7
AT - Austria 6
CH - Svizzera 6
KG - Kirghizistan 6
TH - Thailandia 6
GR - Grecia 4
IL - Israele 4
SI - Slovenia 4
TR - Turchia 4
BD - Bangladesh 3
CL - Cile 3
EU - Europa 3
NL - Olanda 3
PH - Filippine 3
DK - Danimarca 2
EG - Egitto 2
HR - Croazia 2
HU - Ungheria 2
RS - Serbia 2
BG - Bulgaria 1
BJ - Benin 1
CZ - Repubblica Ceca 1
EC - Ecuador 1
ID - Indonesia 1
KH - Cambogia 1
LK - Sri Lanka 1
MD - Moldavia 1
MY - Malesia 1
NG - Nigeria 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PE - Perù 1
PT - Portogallo 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 39.138
Salva come PNG Salva come JPEG
Città #
Wilmington 10.065
Woodbridge 9.292
Houston 9.115
Fairfield 1.283
Ann Arbor 981
Chandler 799
Ashburn 601
Seattle 497
Cambridge 436
Dublin 410
Medford 330
Jacksonville 320
New York 214
Beijing 162
Lawrence 156
Rome 153
Zhengzhou 149
Dearborn 132
Kraków 94
San Diego 77
Redwood City 63
Menlo Park 59
Brussels 44
Nanjing 44
Seoul 41
Shanghai 39
Milan 31
Chengdu 30
Norwalk 30
London 28
Palo Alto 28
Hefei 26
Mülheim 25
Falls Church 20
Mountain View 20
Shenzhen 19
Boardman 18
Esslingen am Neckar 17
San Mateo 17
Toronto 15
Augusta 13
Verona 13
Bassano del Grappa 12
Kunming 12
Guangzhou 11
Chicago 10
Jinan 10
Los Angeles 10
Saint Petersburg 10
Ardabil 9
Center 9
Detroit 9
Kilburn 9
Leawood 9
Wuhan 9
Helsinki 8
Hong Kong 8
Nürnberg 8
Phoenix 8
Scottsdale 8
Changsha 7
Dong Ket 7
Engelhard 7
Padova 7
San Francisco 7
St. George 7
Hounslow 6
Mexico City 6
Nanchang 6
Peshawar 6
Redmond 6
Sydney 6
Indiana 5
Messina 5
Saint Louis 5
Shenyang 5
Tokyo 5
Acton 4
Auburn Hills 4
Aversa 4
Bangkok 4
Bologna 4
Brisbane 4
Council Bluffs 4
Del Norte 4
Durham 4
Fuzhou 4
Lappeenranta 4
Napoli 4
Nottingham 4
Pune 4
Sedico 4
Andover 3
Atlanta 3
Bari 3
Chaoyang 3
Chieti 3
Dhaka 3
Islington 3
Jinhua 3
Totale 36.262
Salva come PNG Salva come JPEG
Nome #
Efficacy and safety of infliximab in psoriatic patients over the age of 65 487
Serum thymosin α 1 levels in patients with chronic inflammatory autoimmune diseases 472
Adalimumab for the treatment of severe psoriasis and psoriatic arthritis 456
Synovial fluid from patients with rheumatoid arthritis modulates monocyte cell-surface phenotype 440
Complement and autoimmunity 438
Peripheral blood natural killer cells and mild thyroid abnormalities in women with reproductive failure 430
Vasculitides and the Complement System: a Comprehensive Review 428
Anti-TNFα discontinuation in rheumatoid and psoriatic arthritis: Is it possible after disease remission? 422
Serological markers associated with disease activity in patients with rheumatoid arthritis treated with rituximab 422
Expression of immunoglobulin-like transcript 4 as an inhibitory receptor in patients with psoriatic arthritis 419
Impact of a multidisciplinary approach in enteropathic spondyloarthritis patients 414
Role of IL-23 in the pathogenesis of psoriasis: A novel potential therapeutic target? 406
Apremilast for the treatment of psoriasis. 405
Self-reported adherence to a home-based exercise program among patients affected by psoriatic arthritis with minimal disease activity 402
C3 come indicatore di efficacia terapeutica in pazienti con artrite reumatoide in terapia con inibitori del TNFα 402
Remission and low disease activity in a cohort of real-life patients with rheumatoid arthritis treated with first-line antitumour necrosis factor 402
Evidence of IL-17 producing innate lymphoid cells in peripheral blood from patients with enteropathic spondyloarthritis 402
Use of anti-tumor necrosis factor alpha therapy in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective analysis of 32 patients 401
Emergence of antinuclear antibodies in psoriatic patients treated with infliximab: personal experience and literature review 401
Role of the complement system in rheumatoid arthritis and psoriatic arthritis: Relationship with anti-TNF inhibitors 400
Association of psoriasis and/or psoriatic arthritis with autoimmune diseases: The experience of two Italian integrated Dermatology/Rheumatology outpatient clinics 399
Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response 399
Efficacy and Safety of Subcutaneous Anti-Tumor Necrosis Factor-Alpha Agents, Etanercept and Adalimumab, in Elderly Patients Affected by Psoriasis and Psoriatic Arthritis: An Observational Long-Term Study 397
Tumour necrosis factor alpha inhibitor therapy and rehabilitation for the treatment of ankylosing spondylitis: A systematic review 392
Golimumab in Patients Affected by Moderate to Severe Psoriatic Arthritis: An Open-Label Study in Thirty-Two Patients Previously Treated with Other Biologics 391
Profile of certolizumab and its potential in the treatment of psoriatic arthritis 391
Evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab: a retrospective study 388
The significance of the development of antinuclear antibodies during infliximab treatment 386
Occurrence of localized scleroderma morphea in a patient with rheumatoid arthritis treated with etanercept 385
Complement system in rheumatoid arthritis: evidence of correlation with disease activity but not with anti-citrullinated protein antibodies 385
Autoantibodies in inflammatory arthritis 383
Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy 382
Two HLA-B27 alleles differently associated with spondylarthritis, B*2709 and B*2705, display similar intracellular trafficking and oligomer formation 382
Resolution with rituximab of localized scleroderma occurring during etanercept treatment in a patient with rheumatoid arthritis 381
Alteration of antigen-independent immunologic synapse formation between dendritic cells from HLA-B27-transgenic rats and CD4+ T cells: selective impairment of costimulatory molecule engagement by mature HLA-B27 380
Resolution of idiopathic recurrent pericarditis in a psoriatic arthritis patient treated with etanercept 379
The autoimmune side of hereditary angioedema: Insights on the pathogenesis 378
The new era for the treatment of psoriasis and psoriatic arthritis: perspectives and validated strategies 377
IL-21 in the pathogenesis and treatment of skin diseases 375
Continuous treatment of plaque-type psoriasis with etanercept: An observational long-term experience 375
Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics 374
Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis 374
Type I lamellar ichthyosis improved by tazarotene 0.1% gel 374
Sistema complementare e artrite reumatoide: Correlazioni con autoanticorpi, caratteristiche cliniche e di laboratorio e farmaci anti-TNF α 369
Complement system in psoriatic arthritis: a useful marker in response prediction and monitoring of anti-TNF treatment. 367
Discontinuation of anti-TNFα therapy due to remission in rheumatoid arthritis: A retrospective study 367
Complement system in psoriatic arthritis: a useful marker and a potential therapeutic target of anti-tnf-alpha treatment 366
Small-medium vessel vasculitides: Is the complement system a potential forgotten target? 364
The interplay between inflammation and metabolism in rheumatoid arthritis 363
Usefulness of QuantiFERON®-TB Gold test in psoriatic patients under treatment with tumour necrosis factor blockers 361
S100A8/A9 in psoriatic plaques from patients with psoriatic arthritis 361
Diagnosis of pigmented skin lesions by dermoscopy: web-based training improves diagnostic performance of non-experts 354
Downregulation of immunoglobulin-like transcript-4 (ILT4) in patients with psoriatic arthritis 353
Auto-reactions, autoimmunity and psoriatic arthritis 350
Skin reaction associated with chrysotherapy: an unusual case 349
Metabolic profiling of human CD4+ cells following treatment with methotrexate and anti-TNF-α infliximab 349
Restoration of peripheral blood natural killer and B cell levels in patients affected by rheumatoid and psoriatic arthritis during etanercept treatment 348
The significance the role of anti-tnf-alpha effects on endothelial dysfunction in psoriasic arthritis 348
Remission of psoriatic arthritis after etanercept discontinuation: analysis of patients' clinical characteristics leading to disease relapse 347
Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways 347
Innate Immune System at the Maternal–Fetal Interface: Mechanisms of Disease and Targets of Therapy in Pregnancy Syndromes 345
A 2-year observational study on treatment targets in psoriatic arthritis patients treated with TNF inhibitors 345
Insights on the role of physical activity in patients with rheumatoid arthritis 342
Elderly psoriatic arthritis patients on TNF-α blockers: results of an Italian multicenter study on minimal disease activity and drug discontinuation rate 338
Morphometric analysis of capillaroscopic images during psoriatic arthritis: comparison with rheumatoid artrhitis 336
Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence 334
Small molecule therapy for managing moderate to severe psoriatic arthritis 333
Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy 326
Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature 325
Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Design, development, and use in therapy 324
Small molecules and antibodies for the treatment of psoriasis: A patent review (2010–2015) 322
The pathogenic role of the complement system in rheumatoid arthritis and its relationship with TNFα inhibitors 320
How to diagnose spondyloarthritis early? Accuracy of peripheral enthesitis detection by power Doppler ultrasonography 311
Successful treatment with intraarticular infliximab for resistant knee monarthritis in a patient with spondylarthropathy: a role for scintigraphy with 99mTc-infliximab 310
From patients’ needs to treatment outcomes in psoriasis: Results from the ‘pSORRIDI’ experience 310
Tofacitinib for the treatment of moderate-to-severe psoriasis 309
The complex interplay between rheumatoid arthritis and atopy: Focus on anti-TNFα treatment 308
Natural killer and b cells in patients with rheumatoid arthritis and psoriatic arthritis treated with etanercept 305
Systemic sclerosis: Exploring the potential interplay between thyroid disorders and pregnancy outcome in an Italian cohort 298
Ultrasound assessment of enthesis thickness in psoriasis and psoriatic arthritis: A cross-sectional study 296
High-dose Intravenous Immunoglobulin for Severe Drug Reactions: Efficacy in Toxic Epidermal Necrolysis 292
Treatment of Hailey-Hailey disease with topical calcitriol 289
Histopathology of the skin in rheumatic diseases 287
null 287
Effects of abatacept on T-lymphocyte sub-populations and immunoglobulins in patients affected by rheumatoid arthritis 286
Factors predicting 2 years of remission and low disease activity in rheumatoid arthritis patients treated with TNF-inhibitors 285
Hereditary angioedema and autoimmunity 281
Radiologically significant joint improvement in a patient affected by psoriatic arthritis treated with adalimumab 274
Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis 271
Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study 267
Evidence for the detection of subclinical retinal involvement in systemic Lupus erythematosus and Sjögren syndrome: a potential association with therapies 266
Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical studies. 265
Anti-LL37 antibodies are present in psoriatic arthritis (PsA) patients: New biomarkers in PsA 261
Interaction between microbiome and host genetics in psoriatic arthritis 230
Challenges in the treatment of Rheumatoid Arthritis 225
Use of synthetic and biological DMARDs in patients with enteropathic spondyloarthritis: a combined gastro-rheumatological approach 212
Successful treatment of psoriatic crumbly nails with ustekinumab 207
Complement, infection, and autoimmunity 198
Evaluation of alexithymia in patients affected by rheumatoid arthritis and psoriatic arthritis: A cross-sectional study 191
Take a look at the eyes in Systemic Lupus Erythematosus: A novel point of view 175
Totale 34.825
Salva come PNG Salva come JPEG
Categoria #
all - tutte 80.664
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 80.664
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20192.806 0 0 0 0 0 0 0 0 0 869 919 1.018
2019/202011.086 806 839 697 912 848 1.295 977 1.042 1.069 1.066 758 777
2020/20218.098 778 962 925 956 894 873 1.029 839 307 210 260 65
2021/20221.716 95 197 160 89 50 86 86 87 97 124 173 472
2022/20232.058 211 177 88 256 188 463 172 135 184 42 104 38
2023/2024855 95 30 36 28 132 272 43 147 58 14 0 0
Totale 39.974